동반진단 시장 : 제공 형태, 기술, 검체 유형, 바이오마커 분류, 용도, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Companion Diagnostics Market is projected to grow by USD 18.48 billion at a CAGR of 10.99% by 2032.

Companion diagnostics (CDx) have become a central operating model for precision medicine, linking a validated diagnostic test to the safe and effective use of a specific therapy. In oncology, rare disease, infectious disease, and immunology, CDx enables clinicians to identify patients most likely to benefit from targeted treatment, avoid ineffective therapies, and support evidence-based reimbursement decisions.

Momentum is reinforced by the rising global cancer burden, broader adoption of next-generation sequencing (NGS), increasing regulatory approvals for biomarker-linked targeted therapies, and expanding clinical use of biomarkers such as EGFR, ALK, BRAF, HER2, BRCA1/2, PD-L1, MSI, NTRK, and KRAS. As drug development becomes more biomarker-led, pharmaceutical sponsors, diagnostic developers, laboratories, and health systems are aligning around integrated clinical validation, regulatory strategy, guideline adoption, and real-world evidence generation.

Transformative Shifts in the Companion Diagnostics Landscape

The companion diagnostics landscape is shifting from single-analyte testing toward multiplex and NGS-based platforms that can evaluate multiple actionable biomarkers from limited tissue or blood samples. This shift supports faster treatment selection, better use of biopsy material, and stronger alignment with modern oncology pathways where several targeted therapy options may be available for one tumor type.

Regulatory and reimbursement expectations are also transforming the sector. Agencies including the U.S. FDA require strong analytical and clinical validation for CDx claims, while payers increasingly assess clinical utility, guideline inclusion, and health-economic value. Liquid biopsy, decentralized testing networks, tumor-agnostic biomarkers, and standardized laboratory quality systems are further changing how precision medicine is delivered across community and academic care settings.

Cumulative Impact of Artificial Intelligence on Companion Diagnostics

Artificial intelligence is influencing companion diagnostics by improving variant interpretation, digital pathology workflows, radiomics, laboratory automation, quality control, and clinical trial matching. AI-enabled tools can help prioritize genomic alterations, detect patterns in pathology images, support biomarker discovery, and synthesize evidence from real-world datasets when appropriately validated.

The cumulative impact of AI is expected to be strongest where it reduces turnaround time, improves reproducibility, and connects multi-omic data with therapy selection. However, adoption depends on transparent validation, representative training datasets, cybersecurity, explainability, clinical workflow integration, and compliance with medical device regulations, HIPAA, GDPR, and emerging AI governance frameworks such as the European Union AI Act.

Key Regional Insights for Companion Diagnostics

North America remains a leading region for companion diagnostics due to strong FDA regulatory pathways, a high concentration of biopharmaceutical innovation, broad molecular testing infrastructure, and rapid adoption of targeted oncology therapies. The United States anchors regional progress through extensive clinical trial activity, national guideline integration, and established laboratory-developed test and in vitro diagnostic ecosystems, while Canada benefits from public health technology assessment processes, provincial oncology programs, and expanding precision medicine initiatives.

Europe is shaped by the In Vitro Diagnostic Regulation, GDPR, national reimbursement systems, and strong translational research networks across Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and ASEAN countries invest in cancer genomics, domestic diagnostic manufacturing, clinical trial capacity, and precision medicine access. Latin America is progressing through private-sector molecular diagnostics adoption and oncology modernization in Brazil and Mexico, while the Middle East is advancing through tertiary care centers, national genomics initiatives, and investment in advanced cancer care. Africa is developing more gradually, supported by regional reference laboratories, public health collaborations, and growing demand for molecular oncology diagnostics in major urban centers.

Key Group Insights Across Global Companion Diagnostics Markets

The European Union is a pivotal group for companion diagnostics because IVDR has increased requirements for clinical evidence, performance evaluation, and notified body oversight, pushing manufacturers toward more rigorous data packages and stronger post-market surveillance. G7 markets provide mature reimbursement frameworks, academic research depth, oncology guideline adoption, and drug development pipelines that support early CDx integration into therapeutic development, while NATO countries benefit from advanced healthcare infrastructure, secure data collaboration priorities, and cross-border clinical research networks.

BRICS countries are increasingly important because of large patient populations, expanding oncology treatment access, and government support for genomics and local diagnostic capacity, particularly in China, India, and Brazil, with Russia and South Africa contributing through regional laboratory infrastructure and evolving precision oncology programs. ASEAN markets are gaining relevance as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expand laboratory networks and oncology services, though reimbursement and infrastructure remain uneven. GCC countries are investing in precision medicine, genomic screening, and advanced cancer centers, positioning the group as a high-potential environment for premium molecular diagnostics and oncology-linked CDx adoption.

Key Country Insights for Companion Diagnostics Adoption

The United States leads in companion diagnostics commercialization through FDA-approved CDx pathways, strong oncology guidelines, high biomedical R&D activity, and widespread use of NGS panels. Canada emphasizes evidence-based adoption through provincial health systems and health technology assessment, while Mexico and Brazil are expanding access through private oncology networks, reference laboratories, and growing demand for targeted therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced oncology care with national reimbursement decision-making, molecular tumor boards, and IVDR-aligned diagnostic standards, while Russia's environment is shaped by local healthcare funding, domestic diagnostic capacity, and access considerations. China is scaling precision oncology through local innovation, hospital-based testing, and large clinical datasets; India is growing through cost-sensitive molecular testing and urban cancer centers; Japan and South Korea benefit from strong regulatory systems, high clinical adoption of advanced diagnostics, and precision oncology programs; and Australia supports adoption through public reimbursement mechanisms, national cancer genomics initiatives, and specialist pathology networks.

Actionable Recommendations for Companion Diagnostics Industry Leaders

Industry leaders should align CDx development with therapeutic development from the earliest clinical phases, ensuring biomarker strategy, assay design, sample logistics, and regulatory requirements are built into trial protocols. Co-development reduces approval risk and improves the probability that a diagnostic will be available when the therapy reaches clinical use.

Organizations should prioritize scalable NGS and liquid biopsy platforms, invest in real-world evidence, and build reimbursement dossiers that demonstrate clinical utility, analytical validity, and cost effectiveness. Strategic partnerships among drug developers, diagnostic manufacturers, reference laboratories, hospitals, academic centers, and digital health providers will be essential for faster turnaround time, equitable access, quality assurance, and broader precision medicine adoption.

Research Methodology for Companion Diagnostics Analysis

This executive summary is developed using a secondary research framework that synthesizes publicly available information from regulatory agencies, clinical guidelines, peer-reviewed biomedical literature, health technology assessment bodies, public health organizations, and recognized scientific sources. Key sources typically include the U.S. FDA, European Commission, national health agencies, WHO, IARC, oncology guideline bodies, and scientific publications covering molecular diagnostics, biomarker testing, and targeted therapy.

The methodology emphasizes triangulation across regulatory approvals, biomarker-linked therapy trends, diagnostic platform adoption, regional healthcare infrastructure, reimbursement dynamics, and technology developments. Insights are validated against observable signals such as CDx approvals, precision oncology programs, NGS utilization, AI governance developments, laboratory quality standards, and expanding clinical use of tissue and liquid biopsy testing.

Conclusion: Companion Diagnostics as a Precision Medicine Growth Engine

Companion diagnostics are no longer a specialized adjunct to drug development; they are a foundational component of precision medicine. As therapies become more biomarker-specific, the ability to deliver accurate, timely, and clinically validated diagnostic results will increasingly determine patient access, treatment selection, and healthcare value.

The sector's evolution is supported by targeted therapy pipelines, expanding NGS adoption, liquid biopsy innovation, AI-enabled interpretation, and global investment in oncology infrastructure. Organizations that integrate regulatory excellence, evidence generation, reimbursement strategy, data governance, and laboratory scalability will be best positioned to lead the next phase of companion diagnostics advancement.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Companion Diagnostics Market, by Offering

• 7.1. Instrumentation
  • 7.1.1. Sample Preparation Systems
  • 7.1.2. Amplification & Detection Instruments
  • 7.1.3. Sequencers & Readers
• 7.2. Reagents & Consumables
  • 7.2.1. Assay Reagent Kits
  • 7.2.2. Primers Probes & Oligonucleotides
  • 7.2.3. Antibodies & Staining Reagents
• 7.3. Software & Bioinformatics
  • 7.3.1. Primary Data Processing
  • 7.3.2. Variant Calling & Annotation
  • 7.3.3. Clinical Interpretation & Reporting
• 7.4. Services
  • 7.4.1. Assay Development & Validation
  • 7.4.2. Clinical Trial Testing
  • 7.4.3. Regulatory & Compliance Support
  • 7.4.4. Data Analytics & Real-World Evidence Support

8. Companion Diagnostics Market, by Technology

• 8.1. Immunoassay Technologies
  • 8.1.1. Immunohistochemistry
  • 8.1.2. ELISA
• 8.2. In Situ Hybridization
• 8.3. Next Generation Sequencing
  • 8.3.1. Targeted Sequencing
  • 8.3.2. Transcriptome Sequencing
  • 8.3.3. Whole Genome Sequencing
• 8.4. Polymerase Chain Reaction (PCR)
  • 8.4.1. Digital PCR
  • 8.4.2. Real time PCR
• 8.5. Microarray Technologies

9. Companion Diagnostics Market, by Sample Type

• 9.1. Tissue
• 9.2. Blood
• 9.3. Urine
• 9.4. Saliva

10. Companion Diagnostics Market, by Biomarker Class

• 10.1. Molecular/Genomic Biomarkers
• 10.2. Protein Biomarkers
• 10.3. Pharmacogenetic Markers
• 10.4. Pharmacodynamic Markers

11. Companion Diagnostics Market, by Application

• 11.1. Autoimmune & Inflammatory Diseases
• 11.2. Infectious Diseases
• 11.3. Oncology
  • 11.3.1. Non-Small Cell Lung Cancer (NSCLC)
  • 11.3.2. Breast Cancer
  • 11.3.3. Colorectal Cancer
  • 11.3.4. Melanoma
  • 11.3.5. Hematologic Malignancies
• 11.4. Neurology
• 11.5. Endocrinology

12. Companion Diagnostics Market, by End User

• 12.1. Academic & Research Organizations
• 12.2. Diagnostic Laboratories
• 12.3. Hospitals
• 12.4. Pharmaceutical & Biotechnology Companies

13. Companion Diagnostics Market, by Distribution Channel

• 13.1. Direct Sales
• 13.2. Distributor Sales
• 13.3. Online Sales

14. Companion Diagnostics Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Companion Diagnostics Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Companion Diagnostics Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. F. Hoffmann-La Roche AG
• 18.2. Abbott Laboratories
• 18.3. Danaher Corporation
• 18.4. Thermo Fisher Scientific Inc.
• 18.5. QIAGEN N.V.
• 18.6. Illumina, Inc.
• 18.7. Agilent Technologies, Inc.
• 18.8. Myriad Genetics, Inc.
• 18.9. Becton, Dickinson and Company
• 18.10. bioMerieux SA
• 18.11. Guardant Health, Inc
• 18.12. ARUP Laboratories
• 18.13. Caris Life Sciences
• 18.14. Almac Group Limited
• 18.15. Siemens Healthineers AG
• 18.16. Sanofi S.A.
• 18.17. Laboratory Corporation of America Holdings
• 18.18. Bio-Rad Laboratories, Inc.
• 18.19. Merck & Co., Inc.
• 18.20. Pfizer Inc.
• 18.21. Quest Diagnostics Incorporated
• 18.22. Abnova Corporation
• 18.23. Agendia, Inc.
• 18.24. Amoy Diagnostics Co., Ltd.
• 18.25. Bio-Techne Corporation
• 18.26. Eli Lilly and Company
• 18.27. ICON PLC
• 18.28. Invivoscribe, Inc.
• 18.29. NeoGenomics, Inc.
• 18.30. PathAI, Inc.
• 18.31. R-Biopharm AG
• 18.32. Sysmex Corporation
• 18.33. Tempus AI, Inc.